Monoclonal Antibodies Market: Revenue Growth, Key Players, Qualitative Analysis, Forecast 2020-2028

The monoclonal antibody market is estimated to represent a global market of USD 135.6 billion by 2025 with growth rate of 4.8%. Biologics industry has been constantly on rise which strongly support the growth of monoclonal antibody market. Due to this fact, the utilization of monoclonal antibody has increased over the past few years owing to the increased awareness of these therapeutics among physicians and patients.For example, in 2012, approximately 20% of the total pharmaceutical revenue generated from biologic products and is anticipated to increase around 25% by the end of 2018.
Furthermore, successful commercialization of monoclonal antibodies like Avastin, Rituxan and Remicade further boosted the customer base. For example, mAbs such as Avastin clocked more than US$ 6 billion of sale across the globe in 2013. Increasing uptake of these therapeutics support the market development.
The market covers the analysis of the commercial or pipeline monoclonal antibody therapeutics such as Humira (adalimumab, anti-TNF), Enbrel, Remicade, Rituxan, Avastin, Herceptin, Lucentis, Erbitux, Eylea and many others.The global market is categorized in terms of source, end use and diseases. Based on source, the market is divided in murine, chimeric, humanized and human. Humanized and human segments are accounted for the largest share of the global market. Reason behind the high growth of this segments as these are considered as a natural drug and offers good safety on in vivo use.Synagis, Herceptin, Zenapax, Myelotarg, Campath, Xolair, Raptiva, Avastin, Tsyabri, Humira, Vectibix , and Cosentyx are some of the examples of human or humanized monoclonal antibodies.
In terms of diseases, the market is segmented as autoimmune diseases, Inflammatory diseases, Infectious diseases and others. The utilization of monoclonal antibody therapeutics in cancer treatments and autoimmune diseases is whooping the market growth. Continuous rise in the incidence rate of cancer and autoimmune diseases along with growing demand for effective therapeutics in these area drive the market growth to great extent. End user segment is divided as hospitals, research laboratories and others. Hospitals segment dominated the market, captured almost 41.23% share of the global market in 2016.

Request to Fill The Form To get Sample Copy of This Report:

Regionally, developed regions such as North America and Europe are considered to be the largest market. Of which, North America accounted for almost 50% share of the global market in 2016. Increasing number of research and development activities coupled with rise in awareness among end users about monoclonal antibody drives the market growth. U.S. based Pfizer, Inc. is currently researching on avelumab—monoclonal antibody for indications such as non-small cell lung cancer, ovarian cancer, and others. These companies spenda significant share of their revenue on research activities, to develop novel mAbs.
Europe is also considered to capture significant market share, 25% global share in 2016. Increasing approval of novel monoclonal antibodies is expected to stimulate the market demand. In 2012, European Medicines Agency (EMA) released guidelines on biosimilar mAb development. This guideline demonstrates the capability of biosimilar mAbs with an interest in development of similar biological mAbs, leading to drive market growth. Asia Pacific and Latin American countries are projected to grow with the promising growth rate during the future period.
Companies such as F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc, Novartis AG; Pfizer; Shanghai Junshi Bioscience Co., Ltd, Daiichi Sankyo Company, Ltd., and others are operating in this market. These companies are engaged in strategic merger and acquisitions to expand their market share in this market. For example, Roche, Inc. acquired California based Genentech which has helped company to expand its market share in monoclonal antibody segment. Aside from Roche, Abbott Laboratories also exhibit strong potential in the monoclonal antibody sector. Growth of this company is attributed to its acquisition of Knoll Pharmaceutical Co. unit and licensing rights to MedImmune’s Synagis and Numax. Further, Johnson & Johnson enhance its market presence supported by the strong growth of Stelara (ustekinumab), Simponi (golimumab), and bapineuzumab.
The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment.
The years considered for the study are:
Historical Year – 2014 & 2015
Base Year – 2015
Estimated Year – 2016
Projected Year – 2025
Traders, Distributors, And Suppliers
Government and Regional Agencies and Research Organizations


The scope of this report covers the market by its major segments, which include as follows:
Autoimmune diseases
Inflammatory diseases
Infectious diseases
Research labs
North America
Asia Pacific
Rest of the World
Further Breakdown of The North America Market
Further Breakdown of The Europe Market
Rest of Europe
Further Breakdown of The APAC Market
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle-East and Africa
Latin America

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.